Research programme: vascular permeability inhibitors - Proaegis Biosciences

Drug Profile

Research programme: vascular permeability inhibitors - Proaegis Biosciences

Alternative Names: CR 014

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator University of Virginia
  • Developer Proaegis Biosciences
  • Class Proteins
  • Mechanism of Action Peptide modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Acute lung injury; Adult respiratory distress syndrome; Inflammation

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Acute-lung-injury in Australia
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Adult-respiratory-distress-syndrome in Australia
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top